|
Causative
Agent
Routes of Exposure
Infective Dose &
Infectivity
Incubation Period
Clinical Effects
Lethality
Transmissibility
Primary Contaminations & Methods of Dissemination
Secondary Contamination & Persistence of organism
Decontamination &
Isolation
Laboratory testing
Therapeutic Treatment
Prophylactic Treatment
Differential Diagnosis
References
Causative
Agent:
Cryptosporidiosis is a parasitic infection
caused by Cryptosporidium parvum.
Route of Exposure:
Fecal-oral, which includes person to person, animal to person,
waterborne, and foodborne transmission.
Infective Dose &
Infectivity:
Less than 10
organisms, and presumably one organism, can initiate an
infection. All people are believed to be susceptible,
though people with intact immune systems may be asymptomatic.
Individuals with impaired immunity and children ages 1 to 5
years old are most likely to become infected.
Incubation Period:
The incubation period is not precisely known; 1-12 days is the
likely range, with an average of about 7 days.
Clinical Effects: Asymptomatic infections are common and constitute a source of
infection for others. The major symptom in humans is
diarrhea, which may be profuse and watery, preceded by
anorexia and vomiting in children. The diarrhea is
associated with cramping abdominal pain. General
malaise, fever, anorexia, nausea and vomiting occur less
often. Symptoms often wax and wane but remit in fewer
than 30 days in most immunologically healthy people. In
patients who are immunocompromised, cryptosporidiosis usually
causes chronic diarrhea; however, rarely, lung and biliary
tract disease also occurs.
Lethality: Cryptosporidiosis is rarely lethal in healthy people. In
persons with severely weakened immune systems, chronic
gastrointestinal illness or more disseminated disease can lead
to complications and death.
Transmissibility:
It is transmitted by ingestion of fecally contaminated food or
water, including water swallowed while swimming; by exposure
to fecally contaminated environmental surfaces; and by the
fecal-oral route from person to person (e.g. while changing
diapers caring for an infected person, or engaging in certain
sexual behaviors).
Primary Contamination & Methods of Dissemination:
In a terrorist attack, C. parvum would most likely be
disseminated through the intentional contamination of food or
water supplies.
Secondary Contamination & Persistence of organism:
Secondary transmission can result from exposure to the stool of
infected individuals, both patients with acute infection and
asymptomatic carriers. Oocysts, the infectious stage, appear
in the stool at the onset of symptoms and are infectious
immediately upon excretion. Oocysts continue to be
excreted in the stool for several weeks after symptoms
resolve; outside the body, they may remain infective for 2-6
months in a moist environment. Oocysts are highly
resistant to chemical disinfectants used to purify drinking
water.
Decontamination &
Isolation:
-
Patients
– No decontamination necessary. Patients
should be treated with standard precautions, with contact
precautions for diapered or incontinent patients. Hand
washing is of particular importance. For hospitalized
patients, enteric precautions in the handling of feces,
vomitus, and contaminated clothing and bed linen; exclusion
of symptomatic individuals from food handling and from
direct care of hospitalized and institutionalized patients;
release to return to work in sensitive occupations when
asymptomatic.
-
Equipment,
clothing & other objects
– Infection control is difficult because of oocyte
resistance to common disinfectants. Heating to 113º F
(45º C) for 5-20 minutes, 140º F (60º C) for 2 minutes, or
chemical disinfection with 10% formalin or 5% ammonia
solution is effective.
Laboratory Testing:
Diagnosis is made by identification of oocysts in stool
samples. However, routine laboratory testing for ova and
parasites will not detect C. parvum. A specific
request for C. parvum testing must be made.
Commercially available tests include ELISA assays for stool,
and a fluorescein-tagged monoclonal antibody is useful for
detecting oocysts in both stool and environmental samples.
Therapeutic Treatment:
Supportive therapy with rehydration as needed
is important. Nitaxozanide suspension (Alina™, Romark
Laboratories) was recently approved by the FDA for treatment
of cryptosporidiosis. If the patient is taking
immunosuppressive drugs, these should be stopped or reduced if
possible.
Prophylactic Treatment:
No vaccine is available.
Differential Diagnosis:
The differential diagnosis for
Cryptosporidium parvum
includes Giardia,
Isospora, microsporidia, Cyclospora,
Clostridium dificile, Salmonella, Shigella,
Campylobacter, Mycobacterium avium complex,
cytomegalovirus, rotavirus, norovirus, and adenovirus.
References:
-
Chin J.
Control of Communicable Diseases Manual, Seventeenth
Edition, American Public Health Association; 2000.
-
Center for
Food Safety and Applied Nutrition. Foodborne Pathogenic
Microorganisms and Natural Toxins Handbook, U.S. Food and
Drug Administration
For more
information call (602) 364-3289 |